Systemic Therapy for Metastatic Renal-Cell Carcinoma
Toni K. Choueiri, Robert John Motzer · New England Journal of Medicine · 2017
Kidney cancers have been extensively studied, and insights from an increased understanding of tumor biology have led to increases in survival rates. Therapies aimed at tumor signaling pathways and immunotherapies have improved the outlook for patients with renal cancer.
Cited by 1,284 works. doi:10.1056/nejmra1601333
Authors
References
- Cancer statistics, 2016
- Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
- Identification of the von Hippel-Lindau Disease Tumor Suppressor Gene
- Renal-Cell Carcinoma
- Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma